All In Biotech

Drug Trial Radar · NCT04788615

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

Open-Label Rater-Blind Randomized Multi-Center Parallel-Arm Active- Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC Monthly vs. First Line DMT - Physician's Choice in the Treatment of Newly Diagnosed RMS

Last checked: Nov 20, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 185 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

185

Actual

Start

Jul 23, 2021

Primary completion

Nov 4, 2025

Study completion Nov 4, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare ofatumumab vs. European approved platform first line self-administered disease modifying therapy (DMT) in newly diagnosed MS patients

Conditions

  • Multiple Sclerosis

Interventions

  • OfatumumabDrug

    20mg Subcutaneous injection

  • First line DMTDrug

    any one of these based on availability at country given as First line DMT Glatiramer acetate 20mg or 40mg or Interferon 22µg or 0.25mg or Peg-Interferon beta-1a 63µg or 125µg or Teriflunomide 14mg or Dimethyl fumarate 120mg or 240mg or Diroximel fumarate 231mg or 462mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with no evidence of disease activity (NEDA-3)Time frame: Baseline to 15 month

Locations

41 sites in 4 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Amiens, France

  • Novartis Investigative Site

    Bordeaux, France

  • Novartis Investigative Site

    Clermont-Ferrand, France

  • Novartis Investigative Site

    Créteil, France

  • Novartis Investigative Site

    Gonesse, France

  • Novartis Investigative Site

    Grenoble, France

  • Novartis Investigative Site

    Montpellier, France

  • Novartis Investigative Site

    Nice, France

  • Novartis Investigative Site

    Nîmes, France

  • Novartis Investigative Site

    Poissy, France

  • Novartis Investigative Site

    Rennes, France

  • Novartis Investigative Site

    Strasbourg, France

  • Novartis Investigative Site

    Bayonne, Bayonne Cedex, France

  • Novartis Investigative Site

    Bayreuth, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Bielefeld, Germany

  • Novartis Investigative Site

    Dortmund, Germany

  • Novartis Investigative Site

    Heidelberg, Germany

  • Novartis Investigative Site

    Siegen, Germany

  • Novartis Investigative Site

    Ulm, Germany

  • Novartis Investigative Site

    Frankfurt am Main, Hesse, Germany

  • Novartis Investigative Site

    Westerstede, Lower Saxony, Germany

  • Novartis Investigative Site

    Cologne, North Rhine-Westphalia, Germany

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Montichiari, BS, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Orbassano, TO, Italy

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Málaga, Spain

  • Novartis Investigative Site

    Seville, Spain

  • Novartis Investigative Site

    Valencia, Spain

  • Novartis Investigative Site

    Santiago Compostela, A Coruna, Spain

  • Novartis Investigative Site

    Salt, Girona, Spain

  • Novartis Investigative Site

    El Palmar, Murcia, Spain

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.